CRDF Q2 2022 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$91,000+33.8% YoY

Gross Profit

$91,000100.0% margin

Operating Income

-$10M-11475.8% margin

Net Income

-$10M-11475.8% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+23.0%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$131M

Total Liabilities

$11M

Stockholders' Equity

$120M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$91,000	$68,000	+33.8%
Gross Profit	$91,000	$68,000	+33.8%
Operating Income	-$10M	-$7M	-51.6%
Net Income	-$10M	-$7M	-54.6%